Radioactive Therapy Shrinks Brain Tumor by 50%

Paul Read, a 62-year-old engineer, has experienced a significant reduction in the size of his aggressive glioblastoma brain tumor, thanks to a new radioactive therapy being trialed at University College London Hospitals NHS Foundation Trust (UCLH). Known as the CITADEL-123 trial, this innovative treatment involves the surgical removal of as much of the tumor as possible, followed by the implantation of an Ommaya reservoir beneath the scalp. This device allows for the direct injection of a drug called ATT001, which delivers low levels of radioactivity to the tumor, effectively killing cancer cells while sparing healthy tissue. Within weeks, Mr. Read's tumor shrank by 50%, providing a beacon of hope for those affected by this typically deadly cancer. The trial's promising results highlight the potential of targeted radioactive therapies in significantly improving the prognosis for glioblastoma patients. Mr. Read expressed gratitude for the trial, viewing it as a lifeline given the aggressive nature of his cancer and the limited survival prospects.